nach oben

Erschienen in:

01.10.2011 | Melanomas

Racial Differences in Survival after Surgical Treatment for Melanoma

verfasst von: Karen Kadela Collins, PhD, Ryan C. Fields, MD, Dadrie Baptiste, MD, Ying Liu, MD, PhD, Jeffrey Moley, MD, Donna B. Jeffe, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Surgical-treatment outcomes for melanoma in African Americans are poorly characterized as a result of low incidence of melanoma among African Americans. We examined differences by race in overall and melanoma-specific survival, stratified by receipt of surgical treatment and by specific types of surgical treatment.

Methods

Data from the 1973–2004 public-use Surveillance, Epidemiology and End Results Program (SEER) were analyzed by Cox proportional hazard models to compare the effects of surgical treatments on overall and melanoma-specific survival in blacks, whites, and other race, controlling for confounding demographic and tumor-related variables.

Results

Of 151,154 patients with first primary melanoma (148,883 whites, 789 blacks and 1,532 other race), 142,653 (94.4%) received surgical treatment. Among patients who received surgical treatment, 10-year melanoma-specific survival was lower in blacks (73%) than in whites (88%) and other race (85%); black patients were at significantly higher risk of overall and melanoma-specific mortality when compared with white (hazard ratio [HR] = 1.64, 95% confidence interval [CI] 1.44–1.86, P < 0.0001 and HR = 1.50, 95% CI 1.25–1.79, P < 0.0001, respectively) and with other race (HR = 1.55, 95% CI 1.31–1.85, P < 0.0001 and HR = 1.49, 95% CI 1.16–1.91, P = 0.0017, respectively). Blacks who underwent biopsy, wide excision and surgery not otherwise specified were at higher risk of overall mortality compared with whites with the same treatment.

Conclusion

Overall and melanoma-specific survival was lower in blacks undergoing surgical treatment for melanoma compared to both whites and other race. Reasons for these disparities remain poorly understood.

National Institutes of Health (2010).SEER Cancer statistics review, 1975–2007. http://seer.cancer.gov/csr/1975_2007/ (July 15, 2010).

Cockburn M, Zadnick J, Deapen D. Developing epidemic of melanoma in the Hispanic population of California. Cancer. 2006;106:1162–8.PubMedCrossRef

Hu S, Parmet Y, Allen G, et al. Disparity in melanoma: a trend analysis of melanoma incidence and stage at diagnosis among Whites, Hispanics and Blacks in Florida. Arch Dermatol. 2009;145:1369–74.PubMedCrossRef

Cormier JN, Xing Y, Ding M, et al. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006;166:1907–14.PubMedCrossRef

Shoo BA, Kashani-Sabet M. Melanoma arising in African-, Asian-, Latino- and Native-American populations. Semin Cutan Med Surg. 2009;28:96–102.PubMedCrossRef

Hemmings DE, Johnson DS, Tominaga GT, Wong JH. Cutaneous melanoma in a multiethnic population: is this a different disease? Arch Surg. 2004;139:968–73.PubMedCrossRef

Rahman Z, Taylor SC. Malignant melanoma in African Americans. Cutis. 2001 67:203–406.

Zell JA, Cinar P, Mobasher M, Ziogas A, Meyskens FL Jr, Anton-Culver H. Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment. J Clin Oncol. 2008;26:66–75.PubMedCrossRef

Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systmatic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer. 2006;106:1431–42.PubMedCrossRef

10.

Eggermont A, Teston A, Marsden J, et al. Utility of adjuvant systemic therapy in melanoma. Ann Oncol. 2009;20(Suppl. 6):30–4.

11.

Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102:493–501.PubMedCrossRef

12.

Testori A, Rutkowski P, Marsden J, et al. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol. 2009;20(Suppl. 6):vi22–9.PubMedCrossRef

13.

Mendenhall W, Amdur R, Grobmeyer S, et al. Adjuvent radiotherapy for cutaneous melanoma. Cancer. 2008;112:1189–96.PubMedCrossRef

14.

America.gov. Increasing diversity predicted in U.S. population: Hispanic and Asian populations both poised to triple. 2004. http://www.america.gov/st/washfile-english/2004/March/20040318124311CMretroP0.4814264.html (July 15, 2010).

15.

Merrill RM, Dearden KA. How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States? Cancer Causes Control. 2004;15:1027–34.PubMedCrossRef

16.

Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S. International classification of diseases for oncology, 3rd edn. Geneva, Switzerland: World Health Organization; 2000.

17.

Greene FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer staging manual, 6th edn. New York: Springer; 2002.

18.

American Cancer Society. Manual for tumor nomenclature and coding. New York: American Cancer Society; 1968.

19.

Shambaugh E. SEER extent of disease: codes and coding instructions. National Cancer Institute; 1984.

20.

Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94:334–57.PubMed

21.

Bellows C, Bellafsy P, Fortang I, Beech D. Melanoma in African Americans: trends in biological behavior and clinical characteristics over two decades. J Surg Oncol. 2001;78:10–6.PubMedCrossRef

22.

Harrison RA, Haque AU, Roseman JM, Soong SJ. Socioeconomic characteristics and melanoma incidence. Ann Epidemiol. 1998;8:327–33.PubMedCrossRef

23.

Polednak A. Prostate cancer treatment in African American and Caucasian men: the need to consider both stage at diagnosis and socioeconomic status. J Natl Med Assoc. 1998;90:101–4.PubMed

24.

Howard G, Anderson RT, Russell G, Howard VJ, Burke GL. Race, socioeconomic status, and cause-specific mortality. Ann Epidemiol. 2000;10:214–23.PubMedCrossRef

25.

Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78–93.PubMedCrossRef

26.

Neal R, Allgar V. Sociodemographic factors and delays in the diagnosis of six cancers: analysis of data from the National Survey of NHS Patients: cancer. Br J Cancer. 2005;92:1971–5.PubMedCrossRef

27.

Bach P, Guadagnoli E, Schrag D, Schussler N, Warren J. Patient demographic and socioeconomic characteristics in the SEER-Medicare database: applications and limitations. Med Care. 2002;40:IV19–25.CrossRef

28.

Ayanian JZ, Chrischilles EA, Wallace RB, et al. Understanding cancer treatment and outcomes: the cancer care outcomes research and surveillance consortium. J Clin Oncol. 2004;22:2992–6.PubMedCrossRef

29.

Williams DR, Neighbors HW, Jackson JS. Racial/ethnic discrimination and health: findings from community studies. Am J Public Health. 2003;93:200–8.PubMedCrossRef

30.

Morton R. Racial differences in adenocarcinoma of the prostate in North American men. Urology. 1994;44:637–45.PubMedCrossRef

31.

Optenberg SA, Thompson IM, Friedrichs P, Wojcik B, Stein CR, Kramer B. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA. 1995;274:1599–605.PubMedCrossRef

32.

Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003;163:49–56.PubMedCrossRef

33.

Shavers VL, Harlan LC, Winn D, Davis WW. Racial/ethnic patterns of care for cancers of the oral cavity, pharynx, larynx sinuses and salivary glands. Cancer Metastasis Rev. 2003;22:25–38.PubMedCrossRef

34.

Freedland S, Isaacs W. Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate. 2005;62:243–2.CrossRef

35.

Hoffman U, Szedlak M, Rittgen W, Jung E, Schadendorf D. Primary staging and follow-up in melanoma patients-monocenter evaluation of methods, costs and patient survival. Br J Cancer. 2002;87:151–7.CrossRef

36.

Streyerberg E, Earle C, Nevile B, Weeks J. Racial differences in surgical evaluation, treatment and outcome of locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol. 2005;23:510–7.CrossRef

37.

Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986–2005. Arch Dermatol. 2009;145:427–34.PubMedCrossRef

38.

Byrd KM, Wilson DC, Hoyler SS, Peck GL. Advanced presentation of melanoma in African Americans. J Am Acad Dermatol. 2004;50:21–4.PubMedCrossRef

39.

Albreski D, Sloan S. Melanoma of the feet: misdiagnosed and misunderstood. Clin Dermatol. 2009;27:556–63.PubMedCrossRef

40.

Hu S, Parker D, Thomas A, Kirsner R. Advanced presentation of melanoma in African Americans: the Miami-Dade County experience. J Am Acad Dermatol. 2004;51:1031–2.PubMedCrossRef

41.

Cress R, Holly E. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians and blacks: an analysis of California Cancer Registry data, 1988–93. Cancer Causes Control. 1997;8:246–52.PubMedCrossRef

42.

Hu S, Soza-Vento RM, Parker DF, Kirsner RS. Comparison of stage at diagnosis of melanoma among hispanic, black, and white patients in Miami-Dade County, Florida. Arch Dermatol. 2006;142:704–8.PubMedCrossRef

43.

Hutchenson A, McGowen J, Maize J, Cook J. Multiple primary and acral melanomas in African Americans: a case series and review of the literature. Dermatol Surg. 2007;33:1–10.CrossRef

44.

Johnson DS, Yamane S, Morita S, Yonehara C, Wong JH. Malignant melanoma in non-caucasians: experience from Hawaii. Surg Clin N Am. 2003;83:275–82.PubMedCrossRef

45.

Parmiani G, Castelli C, Santinami M, Rivoltini L. Melanoma immunology: past, present and future. Curr Opin Oncol. 2007;19:121–7.PubMedCrossRef

46.

Guidry J, Torrence W, Herbelin S. Closing the divide: diverse populations and cancer survivorship. Cancer. 2005;104:2577–83.PubMedCrossRef

47.

SEER. Population characteristics. 2010. http://seer.cancer.gov/registries/characteristics.html (December 17, 2010).

48.

Haass N, Smalley K. Melanoma biomarkers: current status and utility in diagnosis, prognosis and response to therapy. Mol Diag Ther. 2009;13:283–96.

Titel: Racial Differences in Survival after Surgical Treatment for Melanoma
verfasst von: Karen Kadela Collins, PhD
Ryan C. Fields, MD
Dadrie Baptiste, MD
Ying Liu, MD, PhD
Jeffrey Moley, MD
Donna B. Jeffe, PhD
Publikationsdatum: 01.10.2011
Verlag: Springer-Verlag
Erschienen in: Annals of Surgical Oncology / Ausgabe 10/2011
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-011-1706-3

Neu im Fachgebiet Chirurgie

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

Real-World-Daten sprechen eher für Dupilumab als für Op.

14.05.2024 Rhinosinusitis Nachrichten

Zur Behandlung schwerer Formen der chronischen Rhinosinusitis mit Nasenpolypen (CRSwNP) stehen seit Kurzem verschiedene Behandlungsmethoden zur Verfügung, darunter Biologika, wie Dupilumab, und die endoskopische Sinuschirurgie (ESS). Beim Vergleich der beiden Therapieoptionen war Dupilumab leicht im Vorteil.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Racial Differences in Survival after Surgical Treatment for Melanoma